BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts.
Nutraceutix Inc. (Redmond, WA) has obtained a U.S. patent (No. 8,007,777; “Delivery System for Biological Component”) for its BIO-tract probiotic technology. The company has four other international patents for BIO-tract, in China, Australia, Russia, and Singapore, with other patents pending.
Unlike powders, capsules, and cultured foods, BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts, the company says. BIO-tract also benefits from Nutraceutix’s LiveBac process, which is said to extend probiotic shelf life beyond other supplement forms, even at room temperature.
“BIO-tract caplets with LiveBac processing are unparalleled when it comes to the effective delivery of live probiotic organisms to the body,” stated Tim Gamble, Nutraceutix’s president and CEO, in a press release.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.